Search Results for "Crizotinib Src Kinase"

10:56 EST 28th February 2015 | BioPortfolio

Matching Channels

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

Crizotinib (Xalkori) for ALK-positive, locally advanced or metastatic, non-small cell lung cancer – first line

Crizotinib is intended to be used to treat previously untreated non-small cell lung cancer (NSCLC) that has locally advanced or metastasised and expresses the anaplastic lymphoma kinase (ALK) gene. If...

Crizotinib treatment effective against ROS1-positive lung cancer, study suggests

Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial.

Crizotinib treatment effective against ROS1-positive lung cancer

(Massachusetts General Hospital) Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial.

Kinase inhibitors: An allosteric add-on

Development of highly specific kinase inhibitors has been a long-standing challenge in chemical biology. The structural and mechanistic characterization of an Erk1/2 kinase inhibitor provides new stra...

c-jun N-terminal kinase (JNK); MAP kinase 1 (MAPK1; ERK-2); MAP kinase 3 (MAPK3; ERK-1)

Cardiovascular INDICATION: Cardiovascular In vitro and rodent studies suggest ophiopogonin D could help prevent doxorubicin-induced cardiotoxicity.

3-phosphoinositide dependent protein kinase-1 (PDPK1); protein kinase B (AKT; AKT1; PKB; PKBA); ribosomal protein S6 kinase 70kDa polypeptide 1 (RPS6KB1; S6K1)

In vitro studies suggest that small molecule allosteric inhibitors of

FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to an investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non...

Novartis's Lung Cancer Drug Recommended for EU Approval

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia (ceritinib) to treat adult patients with anapl...

Matching PubMed Articles

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.

To the Editor: In the study reported by Shaw et al. (Nov. 20 issue),(1) crizotinib appears to be more potent against the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) than against ...

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.

To the Editor: In the study reported by Shaw et al. (Nov. 20 issue),(1) crizotinib appears to be more potent against the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) than against ...

Successful Crizotinib Rechallenge After Crizotinib-induced Interstitial Lung Disease.

We report the case of a 70-year-old Japanese male diagnosed with advanced lung adenocarcinoma harboring the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. As ...

Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.

Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. However, studies regarding Crizotinib in pancreatic cancer have been limited. Thus, we investigated t...

Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene.

Using cell line-based assays, the secretion of erythroblastic leukemia viral oncogene homologue (ERBB) ligands has been reported to contribute to resistance against crizotinib in lung cancer with the ...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement